Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Prognostic significance of PLA2G4C gene polymorphism in patients with stage II colorectal cancer
Ryhov County Hospital, Jönköping, Sweden.
Ryhov County Hospital, Jönköping, Sweden.
Ryhov County Hospital, Jönköping, Sweden.
Ryhov County Hospital, Jönköping, Sweden.
Show others and affiliations
2016 (English)In: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 55, no 4, 474-479 p.Article in journal (Refereed) Published
Abstract [en]

Background: Phospholipase A2 Group IV C (PLA2G4C) catalyzes the release of certain fatty acids from phospholipids and plays a role in a range of physiological functions, such as remodeling of cell membranes and the production of prostaglandins. Furthermore, it has been proposed that PLA2G4C plays an important role in breast cancer cell chemotaxis. This study aimed to investigate the effect of a single nucleotide polymorphism (SNP) rs1549637 (T>A) of the PLA2G4C gene on the prognosis of colorectal cancer (CRC).

Material and methods: Whole blood DNA was extracted from 381 patients with CRC and 618 controls, and a TaqMan SNP genotyping assay was used to determine the distribution of the genotypes. Cancer-specific and disease-free survival was analyzed by Kaplan-Meier graphs and by uni- and multivariable Cox regression.

Results: The cancer-specific survival differed between the genotypes (p  = 0.019) and the carriers of the A allele were associated with the highest risk of CRC death, with a hazard ratio (HR) of 1.72 [95% confidence interval (CI) 1.17–2.53, p = 0.006] compared with homozygous carriers of the T allele. This increased mortality in the carriers with the allele A was especially marked in stage II with an HR of 3.84 (95% CI 1.51–9.78, p = 0.005).

Conclusion: The A allele in PLA2G4C SNP (rs1549637) is associated with a worse prognosis in patients with CRC, especially in stage II disease, and it could be a potential prognostic biomarker in the planning of individual adjuvant therapy in stage II patients.

Place, publisher, year, edition, pages
2016. Vol. 55, no 4, 474-479 p.
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:hj:diva-27931DOI: 10.3109/0284186X.2015.1073350ISI: 000372125400012PubMedID: 26364726Scopus ID: 2-s2.0-84941254504OAI: oai:DiVA.org:hj-27931DiVA: diva2:853461
Available from: 2015-09-14 Created: 2015-09-14 Last updated: 2016-09-06Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus
By organisation
HHJ, Dep. of Natural Science and BiomedicineHHJ. Biomedical Platform
In the same journal
Acta Oncologica
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 320 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf